<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101129617</journal-id>
<journal-id journal-id-type="pubmed-jr-id">30409</journal-id>
<journal-id journal-id-type="nlm-ta">Genes Brain Behav</journal-id>
<journal-id journal-id-type="iso-abbrev">Genes Brain Behav.</journal-id>
<journal-title-group>
<journal-title>Genes, brain, and behavior</journal-title>
</journal-title-group>
<issn pub-type="ppub">1601-1848</issn>
<issn pub-type="epub">1601-183X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28220990</article-id>
<article-id pub-id-type="pmc">5495606</article-id>
<article-id pub-id-type="doi">10.1111/gbb.12376</article-id>
<article-id pub-id-type="manuscript">NIHMS857129</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Oxidative stress, serotonergic changes and decreased ultrasonic vocalizations in a mouse model of Smith Lemli Opitz Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Sharif</surname>
<given-names>Navila F</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<!--<email>navila.f.sharif@vanderbilt.edu</email>-->
</contrib>
<contrib contrib-type="author">
<name>
<surname>Korade</surname>
<given-names>Zeljka</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="author-notes" rid="FN2">4</xref>
<!--<email>zeljka.korade@unmc.edu</email>-->
</contrib>
<contrib contrib-type="author">
<name>
<surname>Porter</surname>
<given-names>Ned A</given-names>
</name>
<xref ref-type="aff" rid="A4">5</xref>
<!--<email>n.porter@Vanderbilt.Edu</email>-->
</contrib>
<contrib contrib-type="author">
<name>
<surname>Harrison</surname>
<given-names>Fiona E</given-names>
</name>
<xref ref-type="author-notes" rid="FN1">*</xref>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Division of Diabetes, Endocrinology &amp; Metabolism, Department of Medicine, Vanderbilt University Medical Center, 2213 Garland Ave., Nashville, TN 37232, USA</aff>
<aff id="A2"><label>2</label>Neuroscience Program, Vanderbilt University, Nashville, TN, 37232</aff>
<aff id="A3"><label>3</label>Dept. of Psychiatry, Vanderbilt University, Nashville, TN, 37232</aff>
<aff id="A4"><label>5</label>Department of Chemistry, Vanderbilt University, Nashville, TN, 37232</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Corresponding author. <email>Fiona.harrison@vanderbilt.edu</email>, +1-615-875-5547; Fax: +1-615-936-1667</corresp>
<fn fn-type="present-address" id="FN2">
<label>4</label>
<p>Current address: Dept. Pediatrics, Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>20</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>7</month>
<year>2018</year>
</pub-date>
<volume>16</volume>
<issue>6</issue>
<fpage>619</fpage>
<lpage>626</lpage>
<!--elocation-id from pubmed: 10.1111/gbb.12376-->
<abstract>
<p id="P1">Smith Lemli Opitz syndrome is an inherited monogenic disorder in which mutations to the Dhcr7 gene lead to deficits in cholesterol synthesis. As a result, many patients suffer from gross physiological and neurological deficits. The purpose of this study was to identify a potential abnormal behavioral phenotype in a compound mutant mouse model for Smith Lemli Opitz disease (Dhcr7<sup>Δ3–5/T93M</sup>) to further validate the model, and to provide potential targets for future therapeutic interventions. We also sought to identify some of the underlying changes in brain function that may be responsible for behavioral differences among groups. Dhcr7 compound mutant mice were smaller than their single mutant litter-mates. Both single and compound heterozygous mice made fewer ultrasonic vocalizations when separated from the dam which may suggest a communication deficit in these animals. Striking increases of the highly oxidizable 7-DHC were observed in the compound mutant mice. 7-DHC is the precursor to cholesterol and builds up due to decreased function of the mutated Dhcr7 enzyme. Additionally, several differences were noted in the serotonergic system including increased expression of the serotonin transporter (SERT) and increased uptake of serotonin by isolated synaptosomes. We propose that changes to the oxidative environment during development can have a significant impact on the development of serotonergic function and that this contributes to behavioral differences observed in the mutant mice.</p>
</abstract>
<kwd-group>
<kwd>Smith Lemli Opitz Syndrome</kwd>
<kwd>ultrasonic vocalizations</kwd>
<kwd>serotonin</kwd>
<kwd>Oxysterols</kwd>
<kwd>Vitamin E</kwd>
<kwd>SERT</kwd>
<kwd>Mouse model</kwd>
<kwd>Dhcr7</kwd>
<kwd>antioxidant</kwd>
<kwd>development</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>